AVALO THERAPEUTICS, INC. Equity Securities, FV-NI, Gain (Loss)
AVALO THERAPEUTICS, INC. (AVTX) reported Equity Securities, FV-NI, Gain (Loss) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-02.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2022-03-02
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2021-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2021-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2021-06-30 was $0.00.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for fiscal 2020 was $5.21M, a 9556.60% increase from fiscal 2019.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for fiscal 2019 was $53.93K.
- AVALO THERAPEUTICS, INC. equity securities, fv-ni, gain (loss) for fiscal 2018 was $0.00.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Gain (Loss) 12 month | Equity Securities, FV-NI, Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | $0.00 derived: sum of 3 quarters · filed 2022-03-02 | $0.00 10-K · filed 2022-03-02 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-03-02 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-02 | $0.00 10-Q · filed 2021-08-02 | $0.00 derived: sum of 3 quarters · filed 2022-03-02 | $0.00 derived: sum of 4 quarters · filed 2022-03-02 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | $0.00 derived: sum of 3 quarters · filed 2022-03-02 | -$1.87M derived: sum of 4 quarters · filed 2022-03-02 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | -$1.87M derived: sum of 3 quarters · filed 2022-03-02 | $5.21M 10-K · filed 2022-03-02 | $5.21M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | -$1.87M derived: sum of 2 quarters · filed 2021-11-09 | $5.21M 10-Q · filed 2021-11-09 | $5.21M 10-Q · filed 2020-11-09 | $5.26M derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2020-06-30 | -$1.87M 10-Q · filed 2021-08-02 | -$1.87M 10-Q · filed 2020-08-06 | $5.21M 10-Q · filed 2021-08-02 | $5.21M 10-Q · filed 2020-08-06 | $5.26M derived: sum of 3 quarters · filed 2021-08-02 | $5.26M derived: sum of 4 quarters · filed 2021-08-02 | ||
| 2020-03-31 | $7.08M 10-Q · filed 2021-05-13 | $7.08M 10-Q · filed 2020-05-07 | $7.13M derived: sum of 2 quarters · filed 2021-05-13 | $7.13M derived: sum of 3 quarters · filed 2021-05-13 | $7.13M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $53.93K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $53.93K derived: sum of 2 quarters · filed 2021-03-08 | $53.93K derived: sum of 3 quarters · filed 2021-03-08 | $53.93K 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |